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Background: Since many anti-cancer agents act by inflicting DNA damage on
tumour cells, there is increasing interest in the use of inhibitors of DNA repair to
increase the cytotoxicity of these agents. Poly(ADP-ribose) polymerase (PARP) is
an abundant nuclear enzyme that binds to sites of DNA damage and promotes
repair by modifying a number of key proteins. Potent and specific inhibitors of
PARP are available; these have been shown to increase the cytotoxicity of a
range of anti-cancer agents including temozolomide, irinotecan and radiation.
Sources of data: Data from laboratory studies on human tumour cell lines,
pre-clinical studies including tumour xenograft models and early phase clinical
testing in human subjects are discussed.
Areas of agreement: Pre-clinical and early clinical testing indicates that PARP
inhibitors are extremely well tolerated. As single agents they have activity
against BRCA1- and BRCA2-deficient cancers, and in combination they increase
the cytotoxic effects of certain chemotherapy agents.
Areas of controversy: In order for PARP inhibitors to improve outcomes for
patients, their sensitizing effects must be tumour specific. Early clinical data
indicate that systemic toxicity may be exacerbated, so future trials must address
this issue. The mechanism of action of PARP inhibitors in combination with
cytotoxic agents is also uncertain.
Growing points: Among BRCA-deficient cancers, mechanisms of inherent and
acquired resistance to PARP inhibitors are under investigation. Combining these
agents with radiotherapy appears promising but designing clinical trials to test
the efficacy and toxicity of this combination is problematic.
Areas timely for developing research: A particularly promising role for PARP
inhibitors in the treatment of malignant brain tumours is outlined.
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repair/glioblastoma multiforme/PARP inhibittors/temozolomide/irinotecan
British Medical Bulletin 2009; 1–18
DOI:10.1093/bmb/ldp005
& The Author 2009. Published by Oxford University Press. All rights reserved.
For permissions, please e-mail: journals.permissions@oxfordjournals.org
Accepted: January 12,
2009
*Correspondence to:
Dr Anthony J. Chalmers,
Genome Damage and
Stability Centre,
University of Sussex,
Brighton BN1 9RQ, UK.
E-mail: a.j.chalmers@
sussex.ac.uk
 British Medical Bulletin Advance Access published February 9, 2009
Rationale for the use of DNA repair inhibitors
in cancer therapy
Many of the agents used in the treatment of cancer exert their cyto-
toxic effects by damaging the chromosomes of the target tumour cells.
Since the integrity of normal tissues depends on the maintenance of
intact chromosomes, such agents necessarily have unwanted effects.
Indeed, effects on normal tissues generally determine the maximum
dose of an agent that may be safely delivered and are therefore respon-
sible in many cases for the failure of cytotoxic agents to achieve cure.
However, treatment with conventional cytotoxic therapies, such as
ionizing radiation and/or chemotherapy, does deliver clinical benefit, so
tumours in general must deal with DNA damage less efficiently than
normal tissues. By understanding how cellular responses to DNA
damage differ between malignant and healthy cells, it may be possible
to accentuate these differences and enhance the therapeutic ratio
achieved by existing treatments.
Different cytotoxic agents induce different spectra of DNA lesions,
which in turn elicit characteristic DNA damage responses in the cell
(reviewed in Fleck and Nielsen1). The details of these responses are
beyond the scope of this review, but the pathways share a number of
similar features, as shown in Figure 1. Essentially, the chemical nature
of the DNA lesion determines which protein(s) are able to sense it. In
some cases, damage sensing proteins also repair the lesion, but more
commonly binding of sensor proteins to damaged sites initiates a
variety of signalling cascades that alert the cell to the presence of
damaged DNA, minimize the consequences of the damage and activate
appropriate networks of proteins to repair it. Inhibiting any of these
pathways increases the likelihood that DNA damage will cause cell
death—the challenge for translational researchers is to identify targets
that are tumour specific.
An important consequence of DNA damage signalling is the acti-
vation of cell cycle checkpoints (reviewed in Houtgraaf et al.2). The
function of these checkpoints is to protect cells from the adverse con-
sequences of replicating DNA damage (during S phase) or attempting
to execute mitosis in the presence of damaged DNA (Fig. 2).
Defective cell cycle checkpoint responses have been widely documen-
ted in many tumour types and are likely to contribute to the relative
tumour specificity of DNA damaging agents.3 Partly as a result of
blunted cell cycle checkpoint activation, many tumour cells exhibit
rapid proliferation rates that may further increase their susceptibility
to DNA damaging agents. Furthermore, specific repair mechanisms
are required for processing chromosomal damage associated with
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DNA replication. These represent potential therapeutic targets and
are discussed later.
Although less extensive, there is also evidence to suggest that the
actual DNA repair machinery may be compromised in some human
tumours.4 The breast cancer susceptibility proteins BRCA1 and
BRCA2 are components of the homologous recombination (HR) repair
pathway and loss of function of either protein is associated with a pro-
found increase in cancer susceptibility. Interestingly, BRCA1 and
BRCA2 also have putative cell cycle checkpoint roles, as do several of
the other DNA repair proteins that are associated with cancer suscepti-
bility (e.g. ATM and p53). Since one of the features of the DNA repair
network is redundancy—the capacity for alternative proteins or path-
ways to compensate for specific repair deficiencies—there is increasing
interest in the concept of ‘synthetic lethality’. In this scenario,
deficiency of one DNA repair component renders tumour cells highly
sensitive to specific inhibition of a backup pathway that would other-
wise be non-essential.
Fig. 1 Simplified overview of events involved in detection and repair of DNA damage. The
left column indicates the generic sequence of events, which is applicable to many DNA
repair pathways. These are illustrated in the central column with reference to the key
events that occur during base excision repair of single-stranded DNA breaks induced by
ionizing radiation. These events are described in the right column.
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Hence, there is a convincing and increasing body of evidence to indi-
cate that inhibition of DNA damage signalling and/or repair might
enhance the cytotoxicity of DNA damaging agents in a tumour-specific
manner. This review focuses entirely on the therapeutic potential of
inhibiting PARP.
PARP functions in DNA repair
The PARP family of proteins, of which there may be as many as 18
members, is characterized by the enzymatic property of
poly(ADP-ribosylation). This reaction uses NADþ as a substrate and
catalyses the addition of long, branching chains of poly(ADP-ribose)
polymers to target proteins. Such poly(ADP-ribosylation) modulates
the catalytic activity and protein–protein interactions of these targets
and thus influences a range of cellular processes (reviewed in
Fig. 2 Simplified summary of cell cycle checkpoints induced by DNA damage, and the key
signalling proteins and pathways that regulate activation of the G1/S and G2/M
checkpoints.
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D’Amours et al.5). Poly(ADP-ribose) polymerase-1 (PARP-1) is
responsible for at least 80% of total cellular PARP activity, and
together with its nearest relative PARP-2, constitutes the DNA damage
response arm of the PARP family.6 Tankyrase 1 and its close homo-
logue tankyrase 2 are PARP proteins that play regulatory roles in telo-
mere maintenance and mitosis and may therefore influence genomic
stability (reviewed in Hsiao and Smith7), while the remaining members
of the PARP family are not thought to be involved in DNA repair. In
this article, the term ‘PARP’ will be used to indicate the combined
effects of PARP-1 and PARP-2, since in many cases their relative con-
tributions have not been fully elucidated.
PARP-1 and PARP-2 are DNA damage sensors, in that they bind
rapidly to sites of DNA damage, and also DNA damage signallers, in
that this binding activates their catalytic function which in turn modu-
lates a wide range of proteins involved in the DNA damage response
(reviewed in Malanga and Althaus8). The major target is PARP itself:
poly(ADP-ribosylation) of the automodification domain (Fig. 3) creates
a negative charge that brings about dissociation of PARP from DNA.
This is important because it renders damaged DNA accessible to the
proteins that are recruited to execute its repair. Dissociated PARP is
recycled by the action of poly(ADP-ribose) glycohydrolase (PARG),
which enzymatically removes poly(ADP-ribose) polymers.9 PARP
inhibitors disrupt the catalytic function of PARP but do not interfere
with its ability to bind to DNA.10 In the presence of a PARP inhibitor,
therefore, it is probable that PARP binds to sites of damage but fails to
automodify, remaining bound to the lesion, preventing access of repair
factors and exacerbating the impact of PARP inhibitors on DNA
repair.
Although PARP-1 binds to both single- and double-stranded DNA
breaks, its role in single-strand break (SSB) repair via the base excision
repair (BER) pathway has been most clearly defined.11 Even here,
however, complete inhibition of PARP activity by molecular or chemi-
cal means does not abolish SSB repair entirely. Rather, lesions are
repaired with delayed kinetics. The importance of PARP activity in
repair of double-strand breaks (DSB) is even more uncertain and
appears to vary according to the DNA damaging agent involved.
Nevertheless, inhibition or downregulation of PARP has a significant
effect on cellular sensitivity to a range of DNA damaging agents.
BER plays an important role in repairing damaged bases and SSB
induced by alkylating agents and ionizing radiation (reviewed in
Caldecott12). PARP binds both to directly induced SSB and to SSB
that arise during repair of base damage. Such binding appears to
protect these lesions from deleterious interactions with adjacent
DNA. Activated PARP also interacts with BER proteins such as
PARP inhibitors in cancer treatment
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Fig. 3 The role of poly(ADP-ribose) polymerase (PARP) in detecting and signalling single-
stranded DNA breaks (left column), and the effect of chemical inhibition of PARP on this
process (right column). Briefly, the presence of a DNA single-strand break (A) stimulates
attachment of the DNA-binding domain of PARP, which activates the catalytic domain (B).
Poly(ADP-ribosylation) of nuclear proteins occurs, along with poly(ADP-ribosylation) of the
automodification domain of PARP (C). Automodification stimulates release of PARP from
the damaged site, leaving it accessible to DNA repair proteins (D), some of which (e.g. X)
have been recruited and activated by PARP. Others (e.g. Y) are recruited via other path-
ways. Concerted activity of these proteins repairs the damaged site (E). Chemical inhibitors
of PARP compete with NADþ and bind to the catalytic domain (A). The DNA-binding func-
tion of PARP is not affected (B) but catalytic activity is inhibited (C). This prevents auto-
modification of PARP, which remains bound to DNA (D). Recruitment of PARP-dependent
repair proteins (e.g. X) is inhibited, and access of PARP-independent repair proteins (e.g. Y)
to the damaged site is impeded. The DNA break is unrepaired, and inhibited PARP may
remain bound to the damaged site (E). The kinetics of this interaction are unclear.
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XRCC1, promoting recruitment and activity of these factors and
facilitating repair. Hence PARP-1-deficient mice are hypersensitive to
alkylating agents, as are organisms or cells subjected to PARP
inhibition.
DSB induced by ionizing radiation or cytotoxic agents are repaired
primarily by the non-homologous end-joining (NHEJ) pathway,
although lesions arising during DNA replication are preferentially
repaired by the HR pathway (reviewed in O’Driscoll and Jeggo13).
PARP-1 has been shown to interact with components of NHEJ but
does not appear to be a vital component of the pathway. PARP-1 does
not appear to participate in HR,14 indeed inhibition of PARP increases
HR activity in replicating cells, a phenomenon that will be discussed
later. PARP-1-deficient organisms show a modest increase in radiosen-
sitivity; whether this reflects defects in SSB and/or DSB repair has been
a matter of some debate.15
PARP inhibitors
Chemical inhibitors of PARP have been in the laboratory for decades.
The earliest compounds were analogues of the nicotinamide com-
ponent of NADþ, which is the substrate for PARP’s catalytic function.
These inhibitors competed with NADþ for PARP’s catalytic site and
prevented synthesis of poly(ADP-ribose). Since then, a huge array of
more potent inhibitors has been developed, all of which act in essen-
tially the same way. Since the catalytic sites of PARP-1 and PARP-2 are
virtually identical, it has not been possible to develop inhibitors with
differential activity, so the compounds referred to in this article should
be considered as effective inhibitors of both PARP-1 and PARP-2.
While these inhibitors exhibit relative specificity for PARP-1 and
PARP-2, their potential to exert ‘off-target’ effects via other PARPs
should always be considered. For a more detailed review of PARP
inhibitors, see Woon and Threadgill.10
The cellular effects of PARP inhibitors vary according to the cellu-
lar environment. In particular, the presence and nature of DNA
damage and/or metabolic stress have an important impact on the
consequences of PARP inhibition.16 In the presence of damaged
DNA, PARP functions to enhance repair and suppress potentially
deleterious interactions between damaged sites. Because PARP is
abundant and rapidly activated by DNA damage, however, this pro-
tective effect often occurs at the expense of NADþ depletion, since
the reaction catalysed by PARP consumes NADþ. This compound is
essential for the synthesis of ATP, which is required as a source of
energy for a vast array of metabolic processes. High doses of DNA
PARP inhibitors in cancer treatment
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damaging agents have been shown to reduce cellular NADþ levels
by 80% within 5–15 min, and the resulting lack of ATP renders
cells unable to execute cell death by apoptosis, which is an energy-
consuming pathway. Consequently cell death occurs by necrosis,
which is associated with uncontrolled cell lysis and release of inflam-
matory mediators. Pre-treatment with a PARP inhibitor prevents
NADþ depletion and appears to enable cells to execute apoptosis. So
although DNA repair is impaired, the overall damage to tissues or
organs exposed to massive toxic insults may in fact be reduced by
PARP inhibition, as reviewed in Horvath and Szabo.17
This property has been explored in pathological conditions such as
reperfusion after myocardial infarction18 or ischaemic stroke.19 In pre-
clinical models, PARP inhibition appeared to suppress inflammatory
and necrotic tissue responses. Clinical evaluation remains at an early
stage: a recent randomized phase I study of the PARP inhibitor
INO-1001 given immediately prior to coronary artery stenting as
primary treatment for acute myocardial infarction indicated that the
drug was well tolerated and showed a trend towards blunting of the
reperfusion-associated peak in inflammatory markers (C-reactive
protein, interleukin-6) 24 h post-procedure.20 In the context of cancer
treatment, however, the impact of PARP inhibition on DNA repair
pathways appears to be of greater significance than effects on NADþ
metabolism. This may reflect the fact that tumour cells are generally
characterized by rapid replication rates, so efficient repair of DNA
damage is critical to survival. In non-replicating tissues such as the
brain, DNA damage is likely to have less immediate impact than
depletion of NADþ.
Therapeutic effects of PARP inhibitors as single agents
Background
In most cell lines, treatment with PARP inhibitors at doses that success-
fully inhibit PARP activity does not cause cell death, consistent with
the concept that PARP is only activated in the presence of DNA
damage. There was great interest, therefore, in the discovery in 2005
that breast cancer cells bearing homozygous mutations in either the
BRCA1 or BRCA2 cancer susceptibility genes were extremely sensitive
to PARP inhibition.21,22 Investigation of the underlying mechanisms
revealed that both BRCA1 and BRCA2 play important roles in the HR
DNA repair pathway, and that continuous exposure of cycling cells to
a PARP inhibitor resulted in accumulation of DNA DSB that could not
be repaired. The explanation centres on the long-established
A. J. Chalmers
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observation that our chromosomes are continuously subjected to high
levels of damage by reactive chemicals generated within the cell as
by-products of metabolism. PARP is involved in detection and repair of
this endogenous damage, and inhibition of PARP increases the preva-
lence of unrepaired lesions that can cause stalling and collapse of the
DNA replication machinery. As stated earlier, DNA breaks arising
during replication can only be repaired by HR. In BRCA1- or
BRCA2-deficient cells, which lack HR, these lesions go unrepaired and
evolve into cytotoxic DSB.
Based on these observations, PARP inhibitors were proposed as the
ultimate tumour-specific therapy for tumours with BRCA mutations.
Patients generally inherit a single mutant copy of BRCA1 or BRCA2
and develop cancer only when a cell acquires an additional mutation
that inactivates the normal allele. Tumour cells are therefore BRCA1 or
BRCA2 deficient, whereas the cells of the normal tissues retain one
intact copy of the gene, express apparently normal levels of functional
protein and are resistant to PARP inhibition.
Clinical trial data
An initial dose escalation study of the Astra Zeneca compound
AZD2281 confirmed that PARP activity could be successfully inhib-
ited in tumour and white blood cells at non-toxic doses of the
drug, and a number of clinical responses in BRCA-deficient ovarian
cancer were observed.23 A subsequent study confined to patients
with metastatic BRCA-deficient ovarian cancer yielded an overall
response rate of 44%, with median response duration of 30 weeks.
Interestingly, responses were much more frequent in patients whose
tumours were cisplatin sensitive than in cisplatin refractory cases.24
Resistance of BRCA2-deficient cell lines to PARP inhibition has
been shown to be associated with restoration of function of the HR
pathway, and the observation of a similar mechanism underlying
resistance to platinum-based cytotoxic agents may explain this
cross-resistance.25
Similar studies in patients with BRCA-mutated breast or ovarian
cancer are underway in various centres. It will be interesting to see
whether the different PARP inhibitors, which share a very similar mode
of action, will demonstrate different levels of clinical effectiveness.
Other unresolved questions include whether BRCA1-and BRCA2-
deficient cancers are equally sensitive and whether response rates will
be superior in ovarian cancer compared with breast cancer as was the
case in the AZD2281 study.
PARP inhibitors in cancer treatment
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PARP inhibitors and chemotherapy
Data from tumour cell lines
Evidence that PARP inhibition enhances the potency of a range of
cytotoxic agents derives from studies on tumour cell lines in vitro
and from pre-clinical animal models in vivo (Table 1). This evidence
has been comprehensively reviewed elsewhere,26,27 but to summarize,
several different PARP inhibitors have been shown to increase the
cytotoxic effects of alkylating agents such as temozolomide and
topoisomerase I poisons such as irinotecan. Less substantial evidence
exists to support the concept that PARP inhibition enhances tumour
Table 1 In vivo effects of PARP inhibitors in combination with cytotoxic agents
PARP
inhibitor
Cytotoxic agent(s) Model
organism
Tumour type (human
origin unless stated)
Effect Reference
AG14699 Temozolomide Human Malignant melanoma Encouraging
response rates,
exacerbation of
haematological
toxicity
Plummer
et al.40,
Plummer
et al.38
AG14361 Temozolomide,
irinotecan,
radiation
Mouse
xenograft
Colorectal (LoVo,
SW620)
Enhanced tumour
growth delay
Calabrese
et al.32
ABT-888 Temozolomide Mouse
syngeneic,
rat
orthotopic
Mouse melanoma
(B16F10), rat glioma
(9L)
Enhanced tumour
growth delay,
increased survival
Donawho
et al.28
Cisplatin,
carboplatin,
cyclophosphamide
Mouse
xenograft
Breast (MX-1) Enhanced tumour
growth delay
Radiation Mouse
xenograft
Colorectal (HCT-116) Enhanced tumour
growth delay
GPI
15427
Temozolomide Mouse
syngeneic,
mouse
xenograft
(all
intracranial)
Mouse melanoma
(B16), mouse
lymphoma (L5178Y),
glioblastoma
(SJGBM2) (all
intracranial)
Increased survival Tentori
et al.35
CEP-6800 Temozolomide,
irinotecan,
cisplatin
Mouse
xenograft
Glioblastoma (U251),
colorectal (HT29),
non-small cell lung
(Calu-6)
Increased complete
regression rates,
enhanced tumour
growth delay
Miknyoczki
et al.36
CEP-8983 Temozolomide,
irinotecan
Mouse
xenograft
Colorectal (HT29), rat
glioma (RG2)
Enhanced tumour
growth delay
Miknyoczki
et al.33
AZD2281 Temozolomide Mouse
xenograft
Colorectal (SW620) Enhanced tumour
growth delay
Menear
et al.34
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responses to DNA cross-linking agents such as cisplatin.28 The
mechanisms underlying these effects have not been fully elucidated,
and probably vary according to the properties of the cytotoxic
agent. Data relating to temozolomide and irinotecan will be dis-
cussed here.
Temozolomide acts by methylating the DNA bases guanine and
adenine at specific sites. Methylation changes the structure of these
bases so that they pair inappropriately during DNA replication.
Mispaired bases are recognized by the mismatch repair (MMR)
pathway, which attempts to insert the correct base. However, the
methylated base persists, so this cycle is repeated with each round of
DNA replication, eventually resulting in DNA strand breaks and cell
death.
The most cytotoxic lesion is O6-methylguanine, which is repaired pri-
marily by O6-methylguanine methyltransferase (MGMT). Tumours
that express this protein are generally resistant to temozolomide.
Indeed, expression of MGMT by high-grade primary brain tumours
known as glioblastoma multiforme (GBM) is associated with poor
prognosis and resistance to temozolomide.29 In other tumour types,
defects in the MMR pathway are associated with temozolomide resist-
ance, because mispaired bases are not detected, no attempts at repair
are made and no DNA breaks are generated.
Whatever the mechanism of resistance, PARP inhibition has the
potential to reverse it. In the case of MGMT-mediated resistance, the
other methylation products of temozolomide (N7-methylguanine and
N3-methyladenine) are usually non-toxic because they are efficiently
repaired by BER. Inhibition of PARP should therefore render these
lesions cytotoxic and overcome MGMT-mediated resistance. There is
also good evidence that PARP inhibitors have a greater impact on the
temozolomide sensitivity of MMR-deficient than MMR-proficient
tumour cells,30 suggesting that impeding BER-mediated repair of the
N7-methylguanine and N3-methyladenine lesions also overcomes
MMR-related resistance.
Topoisomerase I (topo I) poisons such as irinotecan and topotecan
exert their cytotoxic effects by binding to and stabilizing the DNA heli-
case enzyme topo I. This enzyme plays a vital role in facilitating
unwinding of the DNA double helix during DNA replication to relieve
torsional strain. The mechanism involves temporary insertion of DNA
breaks to allow unwinding, and an intermediate DNA/protein structure
termed the ‘cleavable complex’ is generated. Topo I poisons stabilize
the cleavable complex and extend the lifetime of the associated DNA
strand breaks. PARP-1 is involved in the resolution of these breaks, so
inhibition of PARP activity increases the yield of unrepaired DNA
damage and consequent cell death.31
PARP inhibitors in cancer treatment
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In vivo data from animal models
Several studies have shown potent sensitization of temozolomide by
PARP inhibitors in a range of human tumour cell lines transplanted
as xenografts into animals.32–34 In particular, sensitization of intra-
cranial tumours has been demonstrated for some compounds.35
Likewise, significant improvements in tumour growth delay have been
observed when PARP inhibitors have been added to irinotecan32,33
and, in two reports, cisplatin.28,36 In most cases, PARP inhibition did
not significantly worsen normal tissue toxicity, although it is often
difficult to detect clinically relevant effects on normal tissues in these
animal models. In one study, the intestinal toxicity associated with
irinotecan was found to be reduced by concomitant PARP inhi-
bition37 and another study used a granulocyte-macrophage colony-
forming unit assay to show that PARP inhibition would be unlikely
to exacerbate chemotherapy-related bone marrow toxicity.33 Despite
these results, clinical studies in patients are required to demonstrate
whether the sensitizing effects of PARP inhibitors are truly tumour
specific.
Data from clinical trials
The first clinical trials of a PARP inhibitor in combination with che-
motherapy were performed in patients with metastatic melanoma.
After promising safety and toxicity outcomes from a phase I study of
temozolomide in combination with the Pfizer compound AG014699, a
phase II study was undertaken. Combination therapy yielded encoura-
ging response rates, but the haematological toxicity of temozolomide
was exacerbated.38 There was one toxic death, three neutropenic hospi-
talizations and a temozolomide dose reduction was required in 12 of
the 40 patients. This study illustrates the perennial problem associated
with modifying the cellular response to cytotoxic agents—that of paral-
lel sensitization of the critical normal tissues.
The results of this trial do not necessarily sound the death knell for
the temozolomide/PARP inhibitor combination. Alternative schedules
of temozolomide are available, and daily low-dose regimes cause much
less neutropenia and thrombocytopenia than the 5-day regime that was
used in the trial. It may be possible to enhance the anti-tumour effects
of such alternative regimes while keeping toxicity profiles within accep-
table parameters.
At the time of writing, a number of clinical trials of PARP inhibitors
combined with chemotherapy are either underway or in preparation,
but data are not yet available.
A. J. Chalmers
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PARP inhibitors and radiotherapy
Studies on tumour cell lines
Ionizing radiation induces a combination of SSB and DSB. Of these,
DSB are the lethal lesions, but SSB are approximately 25-fold more
numerous. As previously described, PARP plays a significant role in SSB
repair but its role in DSB repair is disputed. The overall impact of PARP
inhibition appears to be a modest increase in radiosensitivity; this has
been demonstrated in a number of human tumour cell lines39,40 and in
PARP-1-deficient mice.15 Some studies have reported minimal sensitiz-
ation in certain cell lines;41 the likely explanation for this is that the
radiosensitizing effects of PARP inhibitors are dependent on DNA repli-
cation. In non-dividing cells, PARP inhibition causes a delay in SSB
repair which has no impact on DSB formation or cell survival, whereas
in replicating cells the unrepaired SSB generate collapsed replication
forks which give rise to potentially lethal DSB.42 It is not clear whether
PARP inhibition simply increases the burden of unrepaired SSB or has
an additional effect in impeding repair of the collapsed replication forks.
The net result is that PARP inhibition may preferentially sensitize
tumour cells by virtue of their elevated replication rates. This may be
particularly useful in the treatment of high-grade brain tumours where
the critical normal tissue—the brain—is composed almost entirely of
non-dividing cells. The potential role of PARP inhibitors in the treat-
ment of brain tumours will be discussed in more detail later.
In vivo data from animal models
Pre-clinical studies have supported the potential role for PARP inhibi-
tors as radiosensitizers. Tumour growth delay associated with radiation
treatment was enhanced in colorectal cancer xenografts treated with
AG1436132 and in colorectal and lung cancer xenografts treated with
ABT-888.28,43 Combination therapy appeared to be well tolerated in
all cases, although the radiation doses delivered in these experiments
are not comparable with radical doses used in the clinic.
No data from clinical trials combining radiotherapy with PARP
inhibitors were available at the time of writing.
The journey from laboratory to patient
Clinical testing of conventional anti-cancer therapies follows a well-
established pathway. Phase I studies establish the safety and toxicity of
PARP inhibitors in cancer treatment
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a compound, and the treatment of successive cohorts with escalating
doses establishes the maximum tolerated dose (MTD). This dose is
then tested for efficacy and additional toxicity information in phase II
studies. If pre-determined response rates (or other endpoints if appro-
priate) are achieved, the compound may proceed to phase III testing in
which the new agent is compared with current standard therapy in a
randomized manner.
This pathway is not appropriate for evaluating targeted therapies
such as PARP inhibitors for two reasons. First, if the compound can be
shown to completely inhibit the activity of its target at a certain dose,
there is no value in further dose escalation. Hence the first relevant
endpoint is the optimum biological dose (OBD) rather than the MTD.
Since the critical question is whether the agent achieves target inhi-
bition in tumour cells, it is becoming increasingly common for agents
to undergo ‘Phase 0’ testing. In this scenario, patients with a cancer
diagnosis who are due to undergo definitive surgical therapy are
treated with the novel agent immediately prior to surgery. Surgical
resection specimens are then analysed for drug levels (pharmacoki-
netics) and for biological effects (pharmacodynamics) such as PARP
inhibition. Dose escalation during phase 0 enables identification of the
OBD.
Secondly, targeted agents are commonly used in combination with
other agents, such as chemotherapy or radiotherapy, with the aim of
enhancing efficacy. The next stage of testing therefore requires phase I
assessment of the novel agent (given at OBD) in combination with the
intended cytotoxic partner. With any sensitizer there is a risk that toxicity
will be exacerbated, so it is necessary to undertake dose escalation of the
conventional agent to establish its MTD in combination with the new
agent.44 In the ideal scenario, sensitizing effects will be tumour specific
and the conventional agent can be delivered at full dose. Combining novel
therapies with radiation is particularly challenging, since there is only one
opportunity to deliver radical dose radiotherapy, so dose escalation is not
ethically acceptable. New strategies are required for effective testing of the
many targeted therapies, including PARP inhibitors, that have clinical
potential in combination with radiotherapy.
GBM: the ideal tumour target for PARP inhibitors?
GBM are the commonest and most aggressive primary brain tumours.
Current therapy comprises surgical resection followed by radical radio-
therapy with concomitant and adjuvant temozolomide chemotherapy.
Despite such aggressive treatment, median survival is only 1 year. For
elderly or poor performance status patients, average life expectancy is
A. J. Chalmers
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3–6 months. Hence there is an urgent need for novel treatments for
both groups of patients.
A unique feature of GBM is that they exhibit relatively high pro-
liferation rates while the surrounding, dose limiting, normal tissue is
essentially non-dividing. In terms of radiotherapy delivery, it is
necessary to treat large volumes of apparently normal brain to
encompass infiltrative tumour that cannot be removed surgically.
Escalating radiation dose to the normal brain results in debilitating
and irreversible neurotoxicity, so any radiosensitizer must be tumour
specific. Since the radiosensitizing effects of PARP inhibitors are
specific to cells undergoing DNA replication,42 such agents may be
of therapeutic value.
PARP inhibitors also have the potential to increase the sensitivity
of GBM to temozolomide. At least half of GBM are refractory to
temozolomide because they express the repair protein MGMT. These
tumours can be identified using methylation-specific polymerase
chain reaction techniques because the promoter regions of their
MGMT genes are unmethylated. Since PARP inhibition increases the
sensitivity of MGMT expressing tumour cell lines to temozolomide,
the combination of all three agents may be a therapeutic option for
MGMT expressing tumours, for which current therapies are
ineffective.
Summary
PARP activity plays an important role in the sensing and signalling of
DNA damage arising both endogenously and as a result of cytotoxic
treatments. Cancers with defects in the HR DNA repair pathway are
sensitive to PARP inhibitors; clinical trials have shown encouraging
response rates in BRCA1- and BRCA2-deficient ovarian cancers and
have confirmed that PARP inhibitors can be used at effective doses
with minimal toxicity. In a range of common cancer types, PARP
inhibitors enhance the cytotoxicity of a variety of agents that are routi-
nely used in cancer treatment, notably alkylating agents such as temo-
zolomide, topoisomerase I poisons such as irinotecan, and ionizing
radiation. The mechanisms responsible for this sensitization indicate
that GBM are a particularly promising target for PARP inhibitors in
combination with chemotherapy and radiation. Ongoing and future
clinical trials will demonstrate whether the sensitizing effects of these
agents are truly tumour specific and will identify the tumour types,
patient groups and current therapies that benefit most from the
addition of a PARP inhibitor.
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